全文获取类型
收费全文 | 3529篇 |
免费 | 104篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 67篇 |
妇产科学 | 49篇 |
基础医学 | 530篇 |
口腔科学 | 30篇 |
临床医学 | 325篇 |
内科学 | 892篇 |
皮肤病学 | 99篇 |
神经病学 | 301篇 |
特种医学 | 126篇 |
外科学 | 358篇 |
综合类 | 15篇 |
预防医学 | 284篇 |
眼科学 | 40篇 |
药学 | 297篇 |
中国医学 | 10篇 |
肿瘤学 | 220篇 |
出版年
2023年 | 10篇 |
2022年 | 11篇 |
2021年 | 32篇 |
2020年 | 19篇 |
2019年 | 26篇 |
2018年 | 28篇 |
2017年 | 18篇 |
2016年 | 19篇 |
2015年 | 38篇 |
2014年 | 56篇 |
2013年 | 95篇 |
2012年 | 214篇 |
2011年 | 227篇 |
2010年 | 102篇 |
2009年 | 138篇 |
2008年 | 253篇 |
2007年 | 275篇 |
2006年 | 257篇 |
2005年 | 322篇 |
2004年 | 265篇 |
2003年 | 247篇 |
2002年 | 276篇 |
2001年 | 46篇 |
2000年 | 40篇 |
1999年 | 53篇 |
1998年 | 65篇 |
1997年 | 52篇 |
1996年 | 46篇 |
1995年 | 35篇 |
1994年 | 36篇 |
1993年 | 45篇 |
1992年 | 27篇 |
1991年 | 20篇 |
1990年 | 19篇 |
1989年 | 17篇 |
1988年 | 14篇 |
1987年 | 8篇 |
1986年 | 14篇 |
1985年 | 15篇 |
1984年 | 20篇 |
1983年 | 16篇 |
1982年 | 19篇 |
1981年 | 22篇 |
1980年 | 18篇 |
1979年 | 14篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1976年 | 12篇 |
1975年 | 12篇 |
1974年 | 6篇 |
排序方式: 共有3652条查询结果,搜索用时 31 毫秒
101.
Mabo P Defaye P Mouton E Cebron JP Davy JM Tassin A Babuty D Mondoly P Paziaud O Anselme F Daubert JC 《Journal of cardiovascular electrophysiology》2012,23(8):853-860
Impact of Recalls on ICD Utilization . Introduction: The study was designed to evaluate the feasibility and performance of right ventricular (RV) mid‐septal versus apical implantable defibrillator (ICD) lead placement. Methods and Results: SEPTAL is a randomized, noninferiority trial, which randomly assigned patients to implantation of ICD leads in the RV mid‐septum versus apex, with a primary objective of comparing the implant success rate of implant at each site, based on strict electrical predefined criteria. We also compared the (1) pacing lead characteristics, (2) rates of appropriate and inappropriate ICD therapies, and (3) all‐cause mortality between the 2 sites at 1 year. The trial enrolled 215 patients (mean age = 59.7 ± 12.4 years, mean LVEF = 34.0 ± 14.2%, 84.2% men), of whom 148 (68.8%) presented with ischemic heart disease. The ICD indication was primary prevention in 117 patients (54.4%). The lead was successfully implanted in 96/107 patients (89.7%) assigned to the RV mid‐septum, and in 99/108 (91.7%) assigned to the apex (ns). The 1‐year rate of lead‐related adverse events was similar in both groups. A total of 8 first inappropriate ICD therapies (7.9%) were delivered in the RV mid‐septal group, versus 8 (7.8%) in the apical group (ns), while first appropriate therapies were delivered to 22 (21.4%) and 24 patients (23.8%), respectively (ns). All‐cause mortality was 7.9% in the RV mid‐septal versus 2.9% in the RV apical group (ns). Conclusion: This study confirmed the technical feasibility and noninferior performance of ICD leads implanted in the RV mid‐septum versus the apex. (J Cardiovasc Electrophysiol, Vol. 23, pp. 853‐860, August 2012) 相似文献
102.
103.
Atherosclerotic cardiovascular disease (CVD) is a complex disorder that leads to premature death and hospitalization. Several drugs have been, or are currently being tested for their ability to reduce cardiovascular mortality and/or promote regression of atherosclerotic lesions. In addition to "hard end point" clinical trials in which total and cardiovascular mortality as well as risk of incident myocardial infarction are considered as outcomes, trials with surrogate end points using imaging biomarkers can rapidly assess the efficacy of new cardiovascular drugs. Low-density lipoprotein-based therapies with statins have been shown to promote atherosclerosis regression, and several other drugs targeting high-density lipoproteins or inflammation/oxidation are currently being tested in both outcomes and imaging trials in which atherosclerosis regression is anticipated. In this review, we focus on the latest progress in CVD and highlight novel drugs that tackle atherosclerosis as well as the currently used and upcoming imaging techniques to optimally measure atherosclerosis progression. 相似文献
104.
105.
106.
107.
Guillaume Jean Jean-Claude Souberbielle Samuel Granjon Christie Lorriaux Jean-Marc Hurot Brice Mayor Patrik Deleaval Charles Chazot 《Néphrologie & thérapeutique》2013,9(3):154-159
BackgroundBone turnover (BT) abnormalities are frequently observed in patients with chronic kidney disease. Bone biopsy remains the gold standard for diagnosis; however, its invasive nature has led to its decreased utilisation. The serum parathyroid hormone (PTH) level is not a reliable bone marker (BM) for BT assessment. The latest international recommendations suggest the use of total alkaline phosphatase (t-ALP) or bone-specific alkaline phosphatase (b-ALP), but not ß-CrossLaps (CTX). We compared b-ALP, t-ALP, and CTX levels in patients on haemodialysis (HD).MethodsAll HD patients at a single institution following a standard 3 × 4 to 3 × 5 hours schedule were included in the study, provided they were free from liver disease. Serum intact PTH, t-ALP, b-ALP, and CTX values were compared at baseline and after 18 months of treatment. A kinetic study was performed for pre- and postdialysis CTX values over a 2-week period. We described the longitudinal evolution of these BMs in two typical patients.ResultsA total of 98 patients on HD (46% female) were evaluated. The mean age was 69.8 ± 11 years and the mean duration of dialysis was 54.4 ± 61 months. At baseline, CTX (2.1 ± 1 μg/L) correlated well with b-ALP (18 ± 11 μg/L; r = 0.64; P < 0.001) and PTH (221 ± 165 pg/mL; r = 0.62; P < 0.001). The changes in these values at 18 months were also correlated (ΔCTX compared with Δb-ALP: r = 0.51; P < 0.001; Δb-ALP compared with ΔPTH: r = 0.37, P < 0.01). b-ALP and t-ALP (245 ± 132 U/L) were closely correlated (r = 0.78), as was their variation over 18 months (r = 0.67), but t-ALP did not correlate with PTH, and correlated poorly with CTX (r = 0.38). The CTX reduction ratio during standard dialysis was approximately 70 to 75% over each session, although predialysis values remained stable.ConclusionIn HD patients, mean CTX values are five times higher than the normal range. CTX appears to be an alternative to b-ALP for assessing BT. b-ALP remains the standard BM, despite being expensive, infrequently available in many laboratories, and not useful for patients with liver disease. 相似文献
108.
109.
110.
Berry A Balard P Coste A Olagnier D Lagane C Authier H Benoit-Vical F Lepert JC Séguéla JP Magnaval JF Chambon P Metzger D Desvergne B Wahli W Auwerx J Pipy B 《European journal of immunology》2007,37(6):1642-1652
The class B scavenger receptor CD36 is a component of the pattern recognition receptors on monocytes that recognizes a variety of molecules. CD36 expression in monocytes depends on exposure to soluble mediators. We demonstrate here that CD36 expression is induced in human monocytes following exposure to IL-13, a Th2 cytokine, via the peroxisome proliferator-activated receptor (PPAR)gamma pathway. Induction of CD36 protein was paralleled by an increase in CD36 mRNA. The PPARgamma pathway was demonstrated using transfection of a PPARgamma expression plasmid into the murine macrophage cell line RAW264.7, expressing very low levels of PPARgamma, and in peritoneal macrophages from PPARgamma-conditional null mice. We also show that CD36 induction by IL-13 via PPARgamma is dependent on phospholipase A2 activation and that IL-13 induces the production of endogenous 15-deoxy-Delta12,14-prostaglandin J2, an endogenous PPARgamma ligand, and its nuclear localization in human monocytes. Finally, we demonstrate that CD36 and PPARgamma are involved in IL-13-mediated phagocytosis of Plasmodium falciparum-parasitized erythrocytes. These results reveal a novel role for PPARgamma in the alternative activation of monocytes by IL-13, suggesting that endogenous PPARgamma ligands, produced by phospholipase A2 activation, could contribute to the biochemical and cellular functions of CD36. 相似文献